Search - Prime Therapeutics - Portal

23 Results for GLP-1 Pipeline Update

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Real-world study of GLP-1 patients continues to deliver leading insights

PA Sub-Categories: GLP-1 Prime Article: Press Releases
Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

PA Sub-Categories: GLP-1 Prime Article: Press Releases
Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years

Real-world, integrated data follows-up on previous insights, analytics.

PA Sub-Categories: GLP-1 Prime Article: Press Releases
Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

PA Sub-Categories: GLP-1 Specialty drugs Prime Article: Press Releases

Login Portals

Compliance / Legal

Company

© 2026 Prime Therapeutics LLC